What it sells
Mobile-health (SaMD) apps and digital therapeutics for health and medical care, such as pollen allergy and dry-eye apps and VR amblyopia training.
Business model breakdown
Buyer: who owns the budget?
UnverifiedIndividual users (consumer), ophthalmology clinics, and HR/health-management departments at employers.
Trigger: what makes them buy now?
UnverifiedEye discomfort without easy access to an ophthalmologist, and employer health-management (kenko keiei) needs.
Workflow: what inputs become what output?
Collects patient lifestyle data via mobile apps for disease risk visualization, self-management and behavior change, aiming at personalized and preventive medicine.
Economics: what it saves and how it charges
UnverifiedLikely consultation/prescription revenue from online clinic platform plus B2B employee-benefit fees and health-management reports; no figures published.
Distribution: how it reaches customers
Media and self-check apps funnel to online ophthalmology consultations; B2B corporate welfare service; supports telemedicine clinics.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07-16 | Series C | — | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-13.